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Abstract
Background: Ovarian cancer (OvCA) tissues show abundant expression of the ectonucleotidases CD39 and CD73
which generate immunomodulatory adenosine, thereby inhibiting cytotoxic lymphocytes. Little, however, is known
about the effect of adenosine on myeloid cells. Considering that tumor associated macrophages (TAM) and myeloid-
derived suppressor cells (MDSC) constitute up to 20 % of OvCA tissue, we investigated the effect of adenosine on
myeloid cells and explored a possible contribution of myeloid cells to adenosine generation in vitro and ex vivo.
Methods: Monocytes were used as human blood-derived myeloid cells. After co-incubation with SK-OV-3 or
OAW-42 OvCA cells, monocyte migration was determined in transwell assays. For conversion into M2-polarized “TAM-
like” macrophages, monocytes were co-incubated with OAW-42 cells. Ex vivo TAMs were obtained from OvCA ascites.
Macrophage phenotypes were investigated by intracellular staining for IL-10 and IL-12. CD39 and CD73 expression
were assessed by FACS analysis both on in vitro-induced TAM-like macrophages and on ascites-derived ex situ-TAMs.
Myeloid cells in solid tumor tissue were analyzed by immunohistochemistry. Generation of biologically active
adenosine by TAM-like macrophages was measured in luciferase-based reporter assays. Functional effects of adenosine
were investigated in proliferation-experiments with CD4+ T cells and specific inhibitors.
Results: When CD39 or CD73 activity on OvCA cells were blocked, the migration of monocytes towards OvCA cells
was significantly decreased. In vivo, myeloid cells in solid ovarian cancer tissue were found to express CD39 whereas
CD73 was mainly detected on stromal fibroblasts. Ex situ-TAMs and in vitro differentiated TAM-like cells, however,
upregulated the expression of CD39 and CD73 compared to monocytes or M1 macrophages. Expression of
ectonucleotidases also translated into increased levels of biologically active adenosine. Accordingly, co-incubation
with these TAMs suppressed CD4+ T cell proliferation which could be rescued via blockade of CD39 or CD73.
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Conclusion: Adenosine generated by OvCA cells likely contributes to the recruitment of TAMs which further amplify
adenosine-dependent immunosuppression via additional ectonucleotidase activity. In solid ovarian cancer tissue, TAMs
express CD39 while CD73 is found on stromal fibroblasts. Accordingly, small molecule inhibitors of CD39 or CD73
could improve immune responses in ovarian cancer.
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Background
Immune function in the tumor microenvironment is
shaped by tissue-specific and tumor-derived signals [1]
which often decrease the effectiveness of anti-tumor im-
mune responses. This is particularly relevant for malig-
nancies like ovarian cancer (OvCA) where immunological
processes like infiltration with cytotoxic [2] or regulatory
T cells (Treg) [3] heavily affect the prognosis [1, 4, 5]. In
this context, we and others have identified tumor-derived
adenosine as important immunomodulatory factor [6–10].
Adenosine which signals via four specific receptors [11, 12]
can activate several cellular responses which mainly serve
to protect the tissue from excessive inflammatory
responses [12–16]. Sustained high levels of adenosine can,
however, turn harmful by triggering immune suppression
or by activating unremitting wound-healing [17, 18].
Adenosine levels are thus kept low under physiological
conditions, but increased by stimuli such as inflammation,
trauma, hypoxia or ischemia [12]. In ovarian cancer, high
levels of adenosine are due to tumor-specific expression of
the ectonucleotidases CD39/ENTPD1 and CD73/ecto-5′-
nucleotidase [7] which synergistically catalyze the de-
gradation of extracellular immune-stimulatory ATP to
immune-inhibitory adenosine. First, ATP or ADP are
hydrolysed by CD39 to AMP which in turn is dephos-
phorylated to adenosine by CD73 [19–22]. Adenosine can
then suppress anti-tumoral functions of CD4+ or CD8+ T
cells and Natural Killer (NK) cells [7, 9]. This mech-
anism of immunosuppression was also proposed for
CD4+CD25+FoxP3+ Treg cells [20]. OvCA cells, however,
seem to greatly outperform Treg regarding adenosine gen-
eration [7].
Myeloid-derived suppressor cells (M-MDSC) and
tumor associated macrophages (TAM) are infiltrating
myeloid cells which, similar to Treg, significantly impact
survival as they enhance progression and metastasis
[23–26]. In ovarian cancer they build up to 20 % of the
tumor volume [27]. Monocytic and polymorphonuclear
MDSC are recruited by tumors where they can remain
in their relatively immature state. The tumor micro-
environment, however, promotes further differentiation
of monocytic MDSC into TAM [28, 29]. TAM are
alternatively activated M2-macrophages which (as
opposed to inflammatory M1-macrophages) orchestrate
anti-inflammatory, mostly immunosuppressive reactions
[25, 30]. By producing reactive oxygen species (ROS), ni-
tric oxide (NO), indoleamine-2,3-dioxygenase (IDO) and
by secreting high levels of immunosuppressive cytokines
like IL-10 and TGF-β [27], MDSC and TAM significantly
shape the immune contexture of ovarian and other solid
tumors. Clinically, abundance of MDSC and TAM has
been linked to poor outcome in various malignancies
[31, 32] including ovarian cancers of the serous and
mucinous subtype [33, 34]. Interestingly, myeloid cells
seem to accumulate in hypoxic tissue areas [27, 31]
where low oxygen pressure leads to necrotic cell death
with concomitant ATP release. CD39 and CD73 can, how-
ever, convert this pro-inflammatory signal [35–38] into
immunosuppressive adenosine.
While the suppressive effect of adenosine on several
immune cells such as CD4+ and CD8+ T cells and Nat-
ural Killer (NK) cells is well documented, little is known
about the effect of tumor-derived adenosine on myeloid
cells. Moreover, the available data are all based on mur-
ine cells [39–41].
These findings prompted us to investigate the effect of
OvCA-derived adenosine on human monocytes which
are the circulating precursors of both monocytic MDSC
and TAM and can be obtained from peripheral blood. In
addition, we explored a possible regulation of CD39 and
CD73 expression on macrophages in response to the re-
spective mode of differentiation. Finally, we also performed
proliferation assays in vitro in order to functionally confirm
an immunomodulatory role of CD39 and CD73 on M2-
macrophages (or TAM). Within the limits of an ex vivo
study confined to the use of PBMC-derived monocytes to
approximate MDC and TAM, we have thereby obtained
data that suggest a role for adenosine in the accumulation
and function of tumor-associated macrophages.
Methods
Bioinformatic analysis
Gene expression data were obtained from from 285
ovarian cancer samples, from the AOCS (Australian
Ovarian Cancer Study) (GEO ID: GSE9891). Gene ex-
pression was profiled on the affymetrix U133_plus2 plat-
form. Expression data are publicly available from the R2
bioinformatics program (http://R2.amc.nl). Bioinformatic
analysis of microarray data was conducted with the R2
tool by first searching for genes correlated with CD39 in
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ovarian cancer. Subsequently, pairwise correlation ana-
lyses were performed as indicated. To correlate expression
of CD39 and CD73 with overall survival inovarian cancer
patients, we have used the the free online tool Kaplan-
Meier plotter (http://kmplot.com/analysis/index.php?p=
service&cancer=ovar) [42]. 347 patients with stage 3 and 4
(high-grade) serous ovarian cancer were included, regard-
less of p53 status, CA125 levels, optimal/suboptimal
debulking or chemotherapy. A combined classifier com-
prising gene expression data for both CD39/ ENTPD1
(Affymetrix ID 228585) and CD73/NT5E (Affymetrix ID
203939) was bioinformatically computed and survival
probabilities were calculated according to Kaplan-Meier
statistics including 95 % confidence intervals (CIs). For
comparison, two-sided log-rank tests were used.
Immunohistochemistry and immunofluorescence
All tissue specimens (10 ovarian cancer, one healthy ovary)
were provided by the University Hospital Würzburg
(Würzburg, Germany). Samples had been evaluated by at
least two pathologists in routine diagnostics as serous-
papillary OvCA or benign ovary. All human tissue speci-
mens were cut with a microtome (3 μm thickness) and
placed on SuperFrost-Plus slides (Microm International,
Walldorf, Germany). IgG2a-mouse-anti-human CD39
antibody (dilution 1:10; Biozol, Eching, Germany) and
IgG-rabbit-anti-human CD73 antibody (dilution 1:500;
Sigma-Aldrich, St. Louis, MO, USA) were used for
immunohistochemistry. Tissue labelling was performed
using the DiscoveryXT immunohistochemistry system
(Ventana/Roche, Strasbourg, France). After a cell condi-
tioning pre-treatment a 4 min blocking step was per-
formed. The primary antibodies were applied for 32 min,
followed by a secondary OmniMap anti-mouse HRP
(horseradish peroxidase) (Ventana) for 16 min incubation
for anti-CD39 staining and a universal secondary HRP
antibody (Ventana) for 32 min for anti-CD73 staining. For
diaminobenzidine (DAB) visualization, the sections were
incubated with one drop of DAB CM and one drop of
H2O2 CM (Ventana) for 8 min, followed by incubation
with a copper enhancer (Ventana) for 4 min. Human ton-
sil (for anti-CD39) and human placenta (for anti-CD73)
were used as positive controls. Negative controls were
performed by omission of the first antibody. Finally, all
sections were then washed, counterstained with hema-
toxylin and mounted.
For immunofluorescent stainings, 3 μm thick slides
were deparaffinized with xylene and rehydrated in a
descending alcohol sequence. Heat pre-treatment for
antigen retrieval was performed with citrate buffer (pH
6.0) for 40 min, followed by a blocking step for 30 min
(Roti-Immuno Block, dilution 1:10; Roth, Karlsruhe,
Germany) at room temperature. Sections were incubated
with primary antibodies for 1 h at room temperature
(anti-CD39: dilution 1:10 and anti-CD73: dilution 1:500)
and subsequently labelled with secondary antibodies for
1 h each (for CD39: Alexa Fluor488, dilution 1:250, don-
key anti-mouse IgG, Invitrogen, Darmstadt, Germany;
for anti-CD73: Alexa Fluor488, dilution 1:250, goat
anti-rabbit IgG, Invitrogen). Next, the primary anti-
bodies for the double staining were added for 1 h at room
temperature (for anti-CD39: rabbit-anti-human-Iba-1 (di-
lution 1:1000; Wako, Richmond, VA, USA; for anti-CD73:
mouse-anti-human-CD68 (dilution 1:500; Dako, Hamburg,
Germany), followed by an additional secondary antibody
for 1 h (for anti-Iba1: Alexa Fluor568, dilution 1:250,
donkey anti-rabbit IgG, Invitrogen; for anti-CD68: Alexa
Fluor568, dilution 1:250, goat anti-mouse IgG, Invitrogen).
Nuclear counterstaining was performed using Topro-3
(dilution: 1:1000; Invitrogen) followed by sudan black for 5
min to block autofluorescence. Fluorescence images were
analyzed and recorded on a Nikon C1si (Nikon, Japan)
confocal microscope, using the EZ-C1 software. After re-
cording, digital images were further processed and adjusted
for brightness, contrast and color balance.
Cell culture
The human ovarian cancer cell lines SK-OV-3 or OAW-
42 were cultured in RPMI 1640 medium with 10 % FCS,
0.02 % sodium pyruvate, penicillin (100 IU/ml) and
streptomycin (100 μg/ml) (all from Gibco, Karlsruhe,
Germany). Cell line identity was confirmed via single
tandem repeat fingerprinting by the Deutsche Sammlung
für Mikroorganismen und Zellkulturen (Braunschweig,
Germany). Tumor associated macrophages were isolated
from ascites from OvCA patients (n = 9) using anti-
CD14 coated magnetic beads (Miltenyi Biotec, Bergisch
Gladbach, Germany) according to the manufacturer’s
recommendations. For control purposes peritoneal mac-
rophages were isolated from patients with benign ascites
(n = 8). All ascitic fluid punctures were performed for
medical needs.
Migration assay
Peripheral blood mononuclear cells (PBMC) were iso-
lated from the blood of healthy volunteers. To enrich for
monocytes, a two-step gradient centrifugation protocol
was used, starting with a standard Ficoll-based separation
medium (Biocoll, Biochrom, Berlin, Germany) followed by
a Percoll gradient (Easycoll separation medium, Biochrom,
Berlin, Germany). 500.000 monocytes per well were then
placed in the upper inserts of 24-well Transwell plates
(pore diameter 8 μm, membrane thickness 10 μm, cell
growth area 0.33 cm2, Corning, Tewksbury, USA) while
200.000 OAW-42 or SK-OV-3 cells were placed in the
corresponding compartments at the bottom of the plate.
All assays were conducted in RPMI 1640 medium
with 5 % human AB serum (PAA) (500 μl per well).
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After an incubation period of 6 h, all cells from the bot-
tom plates were analyzed by flow cytometry. Monocytes
were identified with anti CD11c-FITC (Immunotools,
Friesoythe, Germany) whereas OvCA cells were stained
with EpCam-APC (BioLegend, San Diego, USA) (both
antibodies used at 1:100 dilution). Dead cells were
excluded via co-staining with 7-aminoactinomycin D. To
quantify the relative migration rate, a standard curve was
generated from several samples containing 2x105 cancer
cells together with different numbers of monocytes (0 -106
cells). To block CD39 or, respectively, CD73 activity
during the transwell co-culture, ARL 67156 (250 μM,
Tocris, Bristol, UK), α,β-methyleneadenosine-5′-diphos-
phate (“APCP”, 100 μM, Sigma, Deisenhofen, Germany)
or appropriate solvent controls were used (Crack et al.,
1995; Krug et al., 1973). As positive control, the meta-
bolically stable adenosine receptor agonist adenosine-5′-
N-ethylcarboxamide (NECA, Tocris) was employed at 100
nM. To control for effects of adenosine on chemokinesis,
a control without tumor cells but with equal amounts of
NECA in both compartments was performed.
RT2 Profiler PCR array for adenosine-dependent
modulation of chemokines and chemokine receptors on
monocytes
To investigate if NECA has an effect on the expression
of chemokines or chemokine receptors in monocytes,
mRNA expression on CD14+ bead-purified monocytes
was assessed 3h after NECA treatment in comparison to
an untreated control. 280ng total RNA per sample were
used for cDNA synthesis (RT2 First Strand Kit, Qiagen,
Hilden, Germany). The RT2 Profiler PCR array for hu-
man chemokines & receptors and the RT2 SYBR Green
ROX qPCR mastermix (both from Qiagen) were used
according to the manufacturer’s instructions. Assays
were run on a StepOnePlus RealTime-PCR cycler (ther-
mofisher, Darmstadt, Germany). For data analysis, the
same threshold was applied for each plate and data were
analyzed in the Qiagen Analysis Webportal. Candidate
molecules appearing to be regulated by NECA in the ar-
rays where then validated by qRT-PCR (Additional file 1).
Determination of M1 and M2 macrophage polarization
and of CD39 and CD73 expression
Monocytes were isolated from healthy volunteers as de-
scribed above and matured in Lumox dishes (Greiner
bio-one, Frickenhausen, Germany) during 7 days in RPMI
1640 with 5 % human AB serum at 37 °C. Polarization
towards M1-phenotype was induced with human recom-
binant IFN-γ [1 μg/ml] and LPS [10 μg/ml] (both from
Peprotech, Hamburg, Germany) for 48h at 37 °C in RPMI
1640 medium with 5 % human AB serum. M2-phenotype
macrophages were generated by co-culture of matured
monocytes with OAW-42 cells in transwell plates (pore
size 1 μm) for 48h at 37 °C in RPMI 1640 with 5 % human
AB serum [43]. M1- and M2-polarization were confirmed
by flow cytometric analysis of intracellular IL-10- and IL-
12-levels [44]; to this aim the cells were stained with anti-
IL10-FITC (Miltenyi) and anti-IL12-APC (Biolegend) at
1:100 dilution. Based on the expression of CD68, macro-
phage purity was found to be >90 %. In addition, arginase
activity was determined in a colorimetric assay based on
urea production. Polarized macrophages were washed
twice with ice-cold PBS, scraped and centrifuged at 1,200
rpm for 5 min. Cell pellets were resuspended into 200 μl
lysis buffer (50 mM Tris–HCl (pH 7.5), 0.1 mM EDTA,
0.1 mM ethylene glycol-bis(β-aminoethyl ether)-N, N, N′,
N′-tetraacetic acid, 1 mM dithiothreitol, 1 μg/ml leupep-
tin, 1 μg/ml aprotinin, and 0.1 mM phenylmethylsulfonyl
fluoride). Cell lysates (50 μl) were added into 50 μl of
50 mM Tris–HCl (pH 7.5) containing 10 mM MnCl2.
Arginase was then activated by heating the mixture at
55–60 °C for 10 min. To allow for catalytic conver-
sion of L-arginine by arginase, lysates were incubated
with 50 μl of L-arginine (0.5 M; pH 9.7) at 37 °C for 1 h,
before the reaction was stopped by addition of 400 μl acid
solution mixture (1 H2SO4:3 H3PO4:7 H2O). For vi-
sualization, 25 μl of 9 % α-Isonitrosopropiophenone (in
100 % ethanol) were added to the mixture and heated at
100 °C for 45 min. Once the samples had been incubated
in the dark for 10 min at RT, the urea concentration was
determined by measuring the absorbance at 550 nm in a
spectrophotometer. The rate of urea production was used
as an index for arginase activity.
Ectonucleotidase expression on M1/M2-macrophages
and on patient-derived TAMs was assessed with anti-
CD73-PE (BioLegend) or anti-CD39-PECy7 (Miltenyi) at
1:100. Specific Fluorescence Indices (SFI) were calculated
for each surface marker by dividing the signal intensity ob-
tained with the specific by the signal intensity measured
with an irrelevant isotype-matched control antibody. All
flow cytometry analyses were performed using a FACSCa-
libur flow cytometer (BD Biosciences, San Jose, USA).
CD39 and CD73 mRNA transcript levels were quanti-
fied from cDNA by semi-quantitative real time PCR
(qRT-PCR) using the ABsolute Blue QPCR SYBR Green
low Rox mix kit and the following primer pairs:
CGGCTACCACATCCAAGGAA (frw) and GCTGGAA
TTACCGCGGCT (rev) for 18S; GTAAGTGACCTTTA
CAAGACCC (frw) and TGCTGGAATGGAAGAGTC
ATC (rev) for CD39; GGCTCCTCTCAATCATGCCG
(frw) and CAGAACATTTCATCCGTGTGT (rev) for
CD73. Purity of the PCR products was assessed based
on the dissociation curve. All samples were measured
in duplicate and Ct (cycle threshold)-values were
within ≤0.5 cycles. mRNA expression was quantified
relative to the expression 18S RNA which was used
as control.
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Adenosine production via CD39 and CD73
Measurement of biologically active adenosine was per-
formed as described before [7, 45]. Briefly, ADORA2A-
overexpressing HEK-293 cells were transiently trans-
fected with the luciferase-encoding RIP1-CRE.luc+
cAMP-reporter plasmid [46]. Transfection efficiency
was normalized via co-transfection of pRL-CMV (Pro-
mega, Madison, WI, USA). As adenosine binding to
ADORA2A activates the adenylate cyclase, a correspond-
ing firefly luciferase signal is obtained. Accordingly, a
standard curve can be generated with a dynamic range
from 20 nM to 40 μM adenosine. Specificity of the signal
is controlled by use of HEK-293 cells without ADORA2A
overexpression and by addition of the ADORA2A-specific
inhibitor SCH58261 (Tocris, Bristol UK). M1- or M2-
macrophages generated as described above were co-
incubated at a 1:1 ratio with of RIP1-CRE.luc- and pRL-
CMV-transfected HEK-293 ADORA2A+ cells for 4 h. Cells
were lysed with passive lysis buffer (Promega) and biopho-
tonic signals were measured using a non-commercial dual
luciferase assay (Dyer et al., 2000). Adenosine concentra-
tions were calculated based on the co-determined standard
curve. All measurements were performed in triplicates
using an Orion II Microplate Luminometer (Berthold De-
tection Systems, Pforzheim, Germany). The specific inhib-
itors ARL67156 for CD39 (100 μM) and APCP for CD73
(100 μM) were added to confirm that the effects depend
specifically on the respective ectonucleotidases.
Proliferation of CD4+ T cells in co-culture with adenosine-
generating cells
CD4 T cell proliferation was measured as before [7]. CD4+
cells were isolated from PBMC using the CD4+ T cell isola-
tion kit II (Miltenyi). Cells were then stained with 2.5 μM
5-(and-6)-carboxyfluorescein diacetate succinimidyl ester
(CFSE, Invitrogen, Karlsruhe, Germany). An agonistic anti-
human CD3 antibody (clone UCHT-1, ImmunoTools) was
immobilized on 96 well Maxisorp-plates (Nunc, Roskilde,
Denmark) by overnight-incubation in PBS (antibody con-
centration: 1 μg/ml). In coated wells, T cell stimulation
could be induced by addition of soluble anti-human CD28
(clone 15E8, 1 μg/ml, Immunotools). In each well, 2x106 T
cells were co-incubated with 5x105 M2 macrophages,
in the absence or presence of the specific inhibitors
ARL67156 for CD39 (100 μM), APCP (100 μM) for CD73
or solvent controls. As positive control, the metabolically
stable adenosine receptor agonist adenosine-5′-N-ethyl-
carboxamide (NECA, Tocris) was used at 10 μM. T cell
proliferation was determined on a FACSCalibur flow
cytometer (BD Biosciences) on day 7 (all [7]).
Statistics
For all experiments, significance was determined by
Student’s t-test. p-values < 0.05 were considered to be
significant. In R2 analysis, p-values were corrected for
multiple testing. In flow cytometric assays at least 50,000
events were counted; two samples were considered to be
significantly different (*) when they were separated by at
least twice the sum of the standard deviations for the
respective regions. A difference exceeding four times the
sum of the respective standard deviations was consid-
ered as highly significant (**).
Results
Expression of CD39 and CD73 in ovarian cancer tissue is
associated with poor survival and correlates with
transcripts expressed in myeloid cells
To check for a possible correlation between CD39 and
CD73 expression and survival in ovarian cancer patients,
a web-based (http://kmplot.com/analysis/index.php?p=
service&cancer=ovar) [42] Kaplan-Meier analysis includ-
ing 347 patients with stage 3 and 4 (high-grade) serous
ovarian cancer was performed. Using a combined classi-
fier for both ectonucleotidases, CD39/CD73high tumors
showed a hazard ratio of 1.32 (95 % CI: 0.99 – 1.76; p =
0.062), thus indicating a trend towards worse survival
for patients with tumors expressing CD39 and CD73 at
significant levels (Fig. 1). Using the R2 database, gene ex-
pression data from 285 ovarian cancer tissues from the
AOCS (Australian Ovarian Cancer Study) were screened
for genes correlating with the presence of CD39
(ENTPD1(209473_at)) or, respectively, CD73 (Additional
file 2: Table S1). Considering the strong correlation be-
tween both ectonucleotidases (r = 0.317, p = 4.3x10−8), a
considerable overlap could also be expected for genes
which tend to be co-expressed with either CD39 or
CD73. In this context, KEGG pathway analysis using the
R2 pathway finder revealed for both CD39 (p = 1.5x10−5)
and CD73 (p = 1.6x10−3) a highly significant correlation
with antigen processing and presentation. 42 out of 57
genes linked to this pathway show correlation with CD39
(p = 1.5x105). Likewise, 41 out of 57 pathway-associated
genes also correlated with CD73 (p = 1.6x10−3) (see
Additional file 3: Table S2). Pairwise correlation analyses
subsequently indicated particularly strong positive cor-
relations with MS4A7 (membrane-spanning 4-domains
subfamily A member 7) (p = 2.5x10−29), myeloid differenti-
ation protein-2, LY96 (p = 2.4x10−34), myeloid cell nuclear
differentiation antigen MNDA (p = 1.1x10−29) and col-
ony stimulating factor 2 receptor beta, CSF2RB (p =
2.4x10−33). Correlation between CD39 and CD68 was
also highly significant (p = 2.4x10−10). Further pathways
linked to CD39 expression include (among others),
cytokine–cytokine receptor interaction (p = 7.9x10−03), cell
adhesion (p = 4.4x10−05) and leukocyte_transendothelial_
migration (p = 8.3x10−03). For CD73 (NT5E), KEGG path-
way analysis showed the strongest association with focal
adhesion (p = 1.2x10−05), followed by cytokine_cytokine_
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receptor_interaction (p = 4.3x10−05), ECM_receptor_inter-
action (p = 4.7x10−04), antigen processing and presentation
(p = 1.6x10−03) and leukocyte transendothelial migration
(p = 1.9x10−03) (see Additional file 2: Table S1). Patterns
resembling specific diseases like tuberculosis, malaria
or amoebiasis or processes like DNA replication or
mismatch repair are not listed here. Pairwise correla-
tions with MS4A7 (p = 3.6x10−14), LY96 (p = 9.1x10−19),
MNDA (p = 5.6x10−18), CSF2RB (p = 6.9x10−12), and
CD68 (p = 3,1x10−6) also showed correlation with CD73
expression. Moreover, phenotypical markers for myeloid
cells (TAM or MDSC) [47] show a significant correlation
with both CD39 and CD73 (see Additional file 4:
Table S3). Possible explanations for these findings are
either expression of ectonucleotidases on myeloid cells in
the tumor tissue, or enhanced recruitment of myeloid cells
when adenosine is generated.
Expression of CD39 and CD73 by macrophages from
ovarian cancer ascites and in ovarian cancer tissue
CD14+ cells were isolated via magnetic cell separation
from fresh ascites samples of OvCA patients. These
monocyte-derived cells which are likely to represent ex
situ-TAMs were found to express both ectonucleotidases
(CD39: 3/3 and CD73: 2/3; Fig. 2). In contrast, macro-
phages and monocytes from healthy donors as well as
peritoneal macrophages from patients with benign dis-
ease showed negligible expression of both CD39 and
CD73 (Fig. 2). With regard to solid ovarian cancer tissue,
expression of CD39 and CD73 in ovarian cancer stroma
was already shown in our previous study (Häusler et al.,
2011). Aiming at a more precise cellular attribution of
ectonucleotidase expression on tumor-associated mye-
loid cells, 10 OvCA cases, 1 healthy ovary and 1 placenta
were investigated. Besides strong endothelial CD39 and
CD73 stainings in both normal and neoplastic tissue re-
gions on all OvCA samples, CD39 was clearly detectable
on tumor-infiltrating immune cells in 7/10 samples with
particularly strong stainings in two cases. Tumor cells,
however, were only focally positive for CD39 with strong
signals in 1/10 and weak stainings in 9/10 OvCA sam-
ples (Fig. 3a; human tonsil serving as positive control as
Fig. 1 Prognostic value of CD39 and CD73 expression in patients
with high-grade serous OvCA. Using the ovarian cancer dataset
available via the free online tool Kaplan-Meier plotter (http://kmplot.
com/analysis/index.php?p=service&cancer=ovar), expression of CD39
and CD73 was correlated with overall survival. All 347 patients with
stage 3 and 4 serous OvCA were included, regardless of p53 status,
CA125 levels, optimal /suboptimal debulking or chemotherapy.
Based on a bioinformatically computed combined classifier comprising
gene expression data for both CD39/ ENTPD1 (Affymetrix ID 228585)
and CD73/NT5E (Affymetrix ID 203939), 134 patients (38.6 %) were
classified as CD39/CD73high. Survival probabilities according to
Kaplan-Meier were calculated together with 95 % confidence intervals
(CIs) and compared using two-sided log-rank tests
Fig. 2 Ectonucleotidases CD39 and CD73 are expressed on CD14+ cells from OvCA ascites. Primary CD14+ cells (TAM) were isolated from OvCA
ascites via magnetic cell sorting (n = 9). For control purposes, macrophages and monocytes from healthy donors (n = 8) and peritoneal macrophages
from patients with benign disease (n = 8) were obtained and analyzed. For statistical comparison, unpaired two-sided Student’s t test was used
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shown in Fig. 3b). In the tumor stroma, CD39 showed a
clear signal in 1/10, but no more than weak focal stain-
ings in 9/10 OvCA samples whereas CD73 was promin-
ently expressed in all cases (Fig. 3c; human placenta
serving as positive control as shown in Fig. 3d). On
tumor cells, CD73 was highly expressed in 1/10 cases,
still prominently in 4/10 tissue samples, weak on 3/10
sections and absent in 2/10 cases. Further CD73 expres-
sion was detected on tumor-infiltrating immune cells in
6/10 cases. To further determine a potential expression
of CD39 and CD73 on myeloid cells, immunofluorescent
double staining with myeloid markers were performed
revealing a co-localization of CD39 with the macrophage
marker IBA-1 (Fig. 3e). CD73, in contrast, was most
prominently expressed on fibroblast-like tumor stromal
cells without showing a co-localization with cells expres-
sion the myeloid marker CD68 (Fig. 3f ). Having found
that TAMs from ascites express CD39 and CD73
whereas myeloid cells in solid tumor tissue express no
CD73 but moderate levels of CD39, ectonucleotidase
levels on TAM or MDSC seems to be context-dependent
and, likely, inducible. This, however, appears insufficient
to explain the strong correlation between CD39, CD73
and myeloid markers found by gene expression analysis.
Consequently, we wondered whether adenosine generated
via ectonucleotidases on stromal or on tumor cells could
attract myeloid cells towards the tumor tissue.
OvCA cells increase the migration of myeloid precursor
cells by CD39- and CD73-dependent generation of
adenosine
To analyze the migration behavior of human blood-
borne myeloid cells, CD14+ monocytes were isolated
from healthy volunteers and placed in the upper inserts
of transwell plates. After 4 h of co-incubation with SK-
OV-3 or OAW-42 cells in the corresponding bottom
Fig. 3 CD39 is expressed on TAM while CD73 is strongly related to tumor stroma in OvCA. Representative immunohistochemical stainings for
(a-b) CD39 and (c-d) CD73 showing that (a) CD39 is heterogeneously expressed on cells within the tumor parenchyma (b: tonsil serving as
positive control) while (c) CD73 expression is largely restricted to the tumor stroma (d: placenta serving as positive control). (e-f) Immunfluorescent
double stainings for (e) CD39 and IBA-1 as well as (f) CD73 and CD68 revealed a considerable co-expression of the macrophages markers with (e)
CD39 but not with (f) CD73
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compartments, migration of monocytes through the
transwell-pores towards the OvCA cells was determined
by flow cytometry. Unfortunately, the difficulties in
measuring the easily degraded nucleoside adenosine did
not allow concomitant determination of adenosine levels
during the assay. However, based on our reporter gene
assay conditions adenosine levels would typically be in
the range from 1.1-1.7 μM for SK-OV-3 and 1.7-4.3 μM
for OAW-42 cells. Under these conditions, pre-treatment
of the tumor cells with the selective CD39- or CD73-
inhibitors ARL67156 or APCP did not affect their viabil-
ity, but reduced monocyte migration by more than half, as
compared to the solvent control. A similar effect was
obtained by adding the A2A receptor inhibitor SCH58261
to the monocytes in the upper compartment. Conversely,
when the metabolically stable adenosine receptor agonist
NECA was applied, monocyte migration was increased by
approximately two third (Fig. 4). Importantly, addition of
NECA overruled the inhibition of CD39 and CD73 which
indicates that the impaired migration was not due to dir-
ect effects of the inhibitors on the monocytes but rather
to the reduced availability of adenosine (Fig. 4). While no
evidence was obtained for enhanced chemokinesis in the
presence of NECA, the co-culture setting does not allow
to distinguish between direct chemotaxis towards adeno-
sine or a more indirect effect by which adenosine might
enhance cell migration towards another tumor-derived
chemokine. Still, to screen whether adenosine might
induce chemokine or chemokine receptor expression on
monocytes, we performed an RT2 Profiler PCR array for
human chemokines & receptors followed by qRT-PCR for
validation of individual candidate molecules (Additional
file 1). This, however, showed only CCL28 and CXCL3/
GRO-γ to be induced by NECA after 3 h. As CCR10
which is the receptor for CCL28 could not be detected,
CCL28 is most unlikely to mediate the observed migratory
effect. CXCL3/GRO-γ has, however, been described to
affect monocyte differentiation and proliferation without
altering their migration behavior [48, 49]. Thus, while an
indirect or secondary effect on migration cannot be ex-
cluded, there is currently no evidence for this. Moreover,
the experimental data show that irrespective of the under-
lying mechanism adenosine can attract monocytes to-
wards tumor cells.
M2-macrophages polarized by coculture with OvCA cells
upregulate CD39 and CD73 to levels also observed in
CD14+ cells from ovarian cancer ascites
Immunosuppressive myeloid cells with a phenotype
resembling tumor-associated macrophages (TAMs) can
be induced by co-incubation of monocytes with OvCA
cells [43]. Having found that OvCA cell-derived adeno-
sine attracts monocytes towards the tumor cells, we
wanted to confirm that these monocytes polarize to an
M2-like phenotype which is characteristic for immuno-
suppressive TAM. Therefore, mature macrophages from
healthy donors were co-incubated with OAW-42 cells in
a transwell setting where macrophage migration to the
Fig. 4 CD39 and CD73 activity on OvCA cells promote monocyte migration in transwell chambers. Primary human monocytes were placed in the
upper inserts of transwell plates while SK-OV-3 (a) or OAW-42 (b) OvCA cells were seeded in the respective bottom compartments. To explore a
potential influence of ectonucleotidases, CD39 activity in tumor cells was inhibited by 100 μM ARL67156 whereas CD73 was inhibited with
100 μM α,β-methyleneadenosine-5′-diphosphate (APCP). Equal amounts of solvent (DMSO) were added to the otherwise untreated controls. To
exclude unwanted effects of the inhibitors on migrating monocytes, ovarian cancer cells were pre-incubated with the inhibitors for 30 min before
being washed with PBS. To assess the effect of adenosine on monocyte migration directly, positive controls with the metabolically stable adenosine
receptor agonist adenosine-5′-N-ethylcarboxamide (NECA) (used at 100 nM) were also included, both in the absence and in the presence of APCP and
ARL67156 (n = 3, * indicates p < 0.05, ** denotes p < 0.01, as assessed by unpaired Student’s t-test). As additional control, A2A receptor signalling was
blocked during the assay by SCH58261 (in a). Under all conditions, migration of monocytes through the 8 μm wide and 10 μm thick pores was
analyzed after 4 h by staining transmigrated cells for CD11c followed by flow cytometric analysis. Tumor cells from the bottom compartment were
identified by co-staining for EpCAM expression
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lower chamber was precluded by the narrow pore-
diameter of the transwell membrane. After 48h of co-
culture, macrophages were analysed by intracellular flow
cytometry for expression of IL-10 and IL-12. As opposed
to M1-polarized macrophages that had been generated
from monocytes in the presence of IFN-γ and LPS, co-
cultured macrophages displayed high levels IL-10 and
low levels of IL-12 confirming their M2-polarization
(Fig. 5a).
High arginase activity is also related to a macrophage
phenotype promoting tumor growth [50]. Consequently,
co-cultured macrophages were further characterized
using a colorimetric assay for arginase activity. This con-
firmed a higher enzymatic activity in the M2 polarized
macrophages as well as in TAMs isolated from fresh
ascites of OvCA patients (Fig. 5b).
Similar to recent reports on murine TAMs [39–41],
human macrophages which had been co-cultured in
vitro with ovarian cancer cells (OAW-42) also showed
high expression of CD39 and CD73, both on mRNA
(Fig. 5c) and on protein level (Fig. 5d). Acquisition of
this phenotype was found to be independent of signaling
via the A2A adenosine receptor since induction of
CD39, CD73 and IL-10 also occurred when SCH58261
was present in the co-culture (Fig. 5e). In M1 macro-
phages, however, CD39 and CD73 surface levels were
much lower (compare Fig. 5a). As this resembled the in
vivo situation observed on TAMs from OvCA ascites
shown in Fig. 2, we decided to further explore the func-
tional consequences of ectonucleotidase expression on
TAM-like M2 macrophages (“in vitro TAMs”).
Increased CD39 and CD73 expression on in vitro
generated TAM-like M2 macrophages translates into
higher levels of biologically active adenosine
To investigate whether the high ectonucleotidase expres-
sion on M2 macrophages results in increased levels of
biologically active adenosine, a luciferase-based adenosine
reporter assay was performed as previously described
[45]. In line with the observed expression of adenosine-
generating enzymes, pro-inflammatory M1-polarized
macrophages produced only low amounts of adenosine
(0.27 μM± 0.18 μM) whereas the TAM-like or M2-
polarized macrophages generated significantly higher
levels of the immunosuppressive nucleoside (on average
3.8 μM, range: 1.6-5.4 μM) (Fig. 3). In the presence of
specific inhibitors for CD39 (ARL 67156) and CD73
(APCP), adenosine production was almost abrogated
(Fig. 6).
In vitro polarized M2 macrophages suppress CD4+ T cell
proliferation via adenosine production
To test the functional relevance of increased adenosine
generation by M2 macrophages, their effect on CD4+ T
cell proliferation was investigated in coculture experi-
ments with CD4+ T cells which had been stimulated
with agonistic antibodies to CD3 and CD28. In this
setting, TAM-like M2 macrophages decreased CD4+ T
cell proliferation by >50 % (52 % on average, range: 47–
56 %) when compared to M1 macrophages (a represen-
tative example is shown in Fig. 7a, pooled data from 3
independent experiments are displayed in Fig. 7b). To
specifically block ectonucleotidase activity on M2 mac-
rophages, ARL67156, APCP, or both were added. Com-
pared to solvent controls, CD4+ T cell proliferation was
increased about 3.5-fold [range: 3.1 - 3.8-fold] by block-
ade of CD39 with ARL67156. Inhibition of CD73 by
APCP enhanced T cell proliferation by a factor of 2.7
[range: 2.4 – 3.0] (Fig. 7). Considering that both APCP
and ARL67156 already abrogated adenosine production
when used on their own (compare Fig. 6), no further
improvement could be expected by their combination.
Instead, a somewhat diminished effect was observed
which may be due to slight toxic effects caused by the
simultaneous use of both inhibitors (Fig. 7).
Discussion
In hypoxic tissues or after chemotherapeutic treatments,
dying tumor cells are abundant. ATP released by these
cells [7, 51–53] constitutes an immunological danger sig-
nal which can activate dendritic cells [35]. ATP can, how-
ever, be rapidly converted to adenosine which is known to
suppress CD4+ T, CD8+ T and NK cells [7, 14, 54]. In fact,
we and others have already shown that ovarian cancer
cells and tissues can express high levels of the ectonucleo-
tidases CD39 and CD73 which enzymatically convert free
extracellular ATP to adenosine. CD39 (which catalyzes
the degradation of pro-inflammatory ATP to AMP) even
showed a highly tumor-specific expression pattern in the
female reproductive tract. CD73 (which generates adeno-
sine from AMP) was likewise significantly overexpressed
in tumor tissues [7]. Moreover, strategies directed at the
inhibition of CD73 (and thus at the prevention of adeno-
sine generation), have shown impressive results in animal
models of breast and ovarian cancer [8, 10, 55]. Neverthe-
less, both positive and negative correlations between
CD39 and CD73 expression and outcome have been
described [56–59]. The desirable analysis whether local
adenosine levels affect prognosis is unfortunately pre-
cluded by the short half-life of adenosine. Gene expression
analysis, however, suggests that combined overexpression
of CD39 and CD73 is associated with a trend towards
poor survival (Fig. 1, p = 0.062, n = 347 patients).
A clear correlation has, in contrast, been found for
infiltration of ovarian tumors with myeloid cells and
rapid tumor progression, metastasis and poor progno-
sis [24–26]. As human studies are confined to readily
available biological materials, we used monocytes as
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Fig. 5 In vitro induced TAM-like macrophages show M2-polarization, arginase activity and ectonucleotidase expression. Peripheral blood
monocytes were obtained from healthy volunteers by gradient centrifugation and subsequent adherence enrichment. Monocytes were then
matured in Lumox dishes for 9 days to obtain mature macrophages (MФ). Macrophage polarization was achieved either with IFN-γ [1 μg/ml] and
LPS [10 μg/ml] (MФ (IFN-γ + LPS)) or by coincubation with OAW-42 OvCA cells (MФ (Co-culture)). a The obtained MФ (IFN-γ + LPS) (light grey)
and MФ (Co-culture) (dark grey) were analyzed by FACS for intracellular IL-10 and IL-12 levels. To obtain specific fluorescence intensity (SFI) values,
the median fluorescence values obtained with fluorochrome-conjugated specific antibodies were divided by the median fluorescence values
obtained with identically labeled irrelevant isotype-matched control antibodies (n = 3, * for p < 0.05, ** for p < 0.01). b CD14+ cells (TAM) were
isolated from malignant tumor tissue. In addition, mature macrophages from a healthy donor were polarized as in a. To determine arginase
activity by MФ (IFN-γ + LPS) and MФ (Co-culture) as well as by TAM, arginine conversion was assessed by measuring the resulting urea in a
colorimetric assay. Significance levels were determined by two-sided, unpaired Student’s t-test. p-values < 0.01 were considered as highly significant
(**). c Macrophages were prepared and polarized as in a. 8 h, 24 h and 48 h after the polarizing conditions had been applied, RNA was isolated,
reverse-transcribed to cDNA and analyzed for CD39 and CD73 transcript levels using SybrGreen-based RT-PCR. 18S rRNA content was determined for
normalization and relative CD39 and CD73 mRNA levels were calculated by the ΔΔCt method using non-polarized macrophages as reference. d Using
MФ (IFN-γ + LPS) and MФ (Co-culture) as in c, CD39 and CD73 surface expression was assessed by flow cytometry. e Macrophages were polarized with
OAW-42 cells for 24 h in the presence or absence of the A2A adenosine receptor inhibitor SCH58261 before IL-10, CD39 and CD73 expression were
analysed by flow cytometry. Comparable data for primary TAMs isolated from OvCA ascites are shown in Fig. 2
Montalbán del Barrio et al. Journal for ImmunoTherapy of Cancer  (2016) 4:49 Page 10 of 16
easily available human myeloid cells and co-cultured
them with ovarian cancer cells, thereby mimicking the
maturation and M2 differentiation of myeloid cells in the
tumor microenvironment [43]. CD14+ cells derived from
ascites (Fig. 2) were used ex vivo to corroborate the in
vitro findings. Based on these cellular model systems, we
could show that OvCA-derived adenosine exerts direct or
indirect chemotactic effects on human monocytes (Fig. 4)
and is thus likely to attract myeloid precursor cells to-
wards the tumor tissue. Moreover, in a microenvironment
that is shaped by OvCA cells, human monocytes differen-
tiate into M2-polarized macrophages or TAM (Fig. 5)
which express IL-10 rather than IL-12 and show arginase
activity. While signalling via the A2A adenosine receptor
is not required for M2 polarization, M2 macrophages ex-
press significant levels of the adenosine-generating ecto-
nucleotidases CD39 and CD73, both on mRNA and
protein level (Fig. 6). This is in line with recent reports on
CD73 expression by murine MDSC which were also
shown to suppress immune responses in an adenosine-
dependent way [19, 39, 40]. Moreover, CD14+ cells iso-
lated from OvCA ascites also showed much higher levels
of CD39 and, in particular, CD73 than macrophages from
non-malignant control ascites (Fig. 2). Interestingly, similar
findings were also reported in a most recent publication
describing an IL-27 dependent induction of CD39 on mac-
rophages in ovarian cancer patients [60]. Using a reporter
gene assay developed in our laboratory [45], we could then
confirm that the amount of biologically active adenosine
generated by M2 macrophages was similar to the levels
produced by OvCA cells [7], i.e., in the low micromolar
range (Fig. 4) and thus 30-60-fold higher than the already
immunosuppressive levels from Treg [45]. Consequently,
co-culture experiments also confirmed that M2 macro-
phages exert strong anti-proliferative effects on activated
CD4+ T cells. Importantly, T cell proliferation was largely
restored when CD39 or CD73 were blocked by ARL67156
or APCP, respectively, thereby confirming the pivotal role
of adenosine in the observed T cell inhibition (Fig. 7).
While these data show that ectonucleotidase expres-
sion by myeloid cells may be functionally relevant, an
attribution to either MDSC or TAM was not attempted
in our study. As monocytic MDSC which are predomin-
ant in tumor tissues [28, 29] tend to rapidly differentiate
into TAM [61], discrimination between these cell types
is difficult and gradual. Polymorphonuclear MDSC, in
contrast, do not develop into TAM and should thus be
seen as different cell population [62]. Using common
myeloid markers, immunohistochemical analysis of solid
ovarian tumor tissue failed to show a co-localization of
CD73 with CD68 (Fig. 3f ). CD39, in contrast, could be
co-stained with the macrophage marker IBA-1 (Fig. 3e).
While the limited sensitivity of immunohistochemical
analysis may also contribute to the apparent lack of
CD73 on TAM or MDSC in solid ovarian cancer tissue,
expression of ectonucleotidases on myeloid cells may
also be context-dependent and could require e.g., in-
flammatory stimuli as found in ascites or under in vitro
conditions. Still, both CD39 and CD73 were detected on
both tumor and stromal cells in ovarian cancer tissue
and prominent expression was found on endothelial cells
from the tumor vasculature. Infiltrating immune cells
may thus be already exposed to adenosine during transmi-
gration into the tissue. Further, recruitment of macrophage
precursor cells via adenosine-dependent chemotaxis may
be particularly efficient when adenosine is generated at the
tumor-vessel interface. The partial co-expression between
CD39 and IBA-1+ cells is certainly insufficient to fully
Fig. 6 Macrophages from in vitro co-culture with OvCA cells
generate adenosine via CD39 and CD73. Human macrophages were
generated and polarized in transwell coculture with OAW-42 OvCA
cells. For control purposes, M1 macrophages were induced with
LPS (10 μg/ml) and IFN-γ (1 μg/ml). After coculture with ADORA2A-
overexpressing, RIP1-CRE transfected sensor cells, a luciferase-based
reporter assay was performed to determine production of biologically
active adenosine [45]. To confirm that adenosine generation depends
on ectonucleotidase activity, CD39 was blocked with ARL67156 (MФ
(Co-culture) + ARL) during coculture. Likewise, CD73 was inhibited by
APCP (MФ (Co-culture) + APCP) and to inactivate both ectonucleotidases,
ARL67156 and APCP were also combined (MФ (Co-culture) + ARL +
APCP). To the control groups (MФ (Co-culture) and MФ (IFN-γ + LPS)),
only the solvent DMSO was added (n = 3). Significance levels were
determined by Student’s t-test. p-values < 0.01 were considered as
highly significant (**)
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account for the strong correlation between macrophage-
specific genes and ectonucleotidase expression (Additional
file 2: Table S1 and Additional file 3: Table S2) or for the
highly significant association between CD39, CD73 and the
KEGG data set for antigen processing and presentation
(Additional file 4: Table S3). An additional adenosine-
dependent recruitment of myeloid cells to the tumor
microenvironment may therefore also have contributed to
the strong correlations found by unbiased transcriptome
analyses from 285 ovarian cancer tissues.
As this study aimed at establishing a link between
adenosine and myeloid cells in the tumor microenviron-
ment, the mechanism responsible for the adenosine-
dependent recruitment of monocytes towards tumor
cells was not investigated in detail. In the literature, di-
verse effects of adenosine on cell migration have already
been reported: While ATP enhances the non-directional
motility of monocytes [63], degradation of ATP to adeno-
sine by CD39 was found to promote the chemotactic mi-
gration of myeloid cells in a modified Boyden chamber
Fig. 7 “TAM-like” macrophages suppress CD4+ T cell proliferation via a CD39 and CD73-dependent mechanism. Polarized macrophages were
generated in co-culture with OAW-42 OvCA cells whereas M1 macrophages were induced by treatment with LPS and IFN-γ. CD4+ T cells were
isolated from healthy volunteers and stained with CFSE before activation with plate-bound anti-CD3 and soluble anti-CD28 antibodies. Activated
CFSE+ CD4+ T cells were then co-incubated with M2 macrophages in the absence (T + MФ (Co-culture)) or presence of CD39 or CD73-inhibitors
ARL67156 (T + MФ (Co-culture) + ARL) or, respectively, APCP (T + MФ (Co-culture) + APCP), or a combination of both (T + MФ (Co-culture) + ARL +
APCP). T cell proliferation was determined by flow cytometry via CFSE dilution, as described previously [7] (n = 3, ** indicates p < 0.01 as assessed
by unpaired, two-sided Student’s t-test). While a representative histogram is shown in a, mean values from three independent experiments are
depicted in (b)
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assay. Consequently, chemotaxis of CD39-deficient mono-
cytes/macrophages was impaired [64]. As this effect could
also be rescued by addition of NECA, it is fully consistent
with our observations made with ARL67156 and NECA.
Similar findings on adenosine and cell migration were
reported for neutrophils and initially attributed to the in-
volvement of the A2 adenosine receptor [65]. Later, an
addtitional and possibly stronger contribution from the
A1 adenosine receptor was described [66]. In a more com-
plex system involving a pericellular matrix and smooth
muscle cells, adenosine also promoted the migration of
monocytes/macrophages and their trapping in the intersti-
tial matrix. This, however, was ascribed to an indirect ef-
fect caused by hyaluronic acid synthase being induced via
the A2B, A2A and A3 adenosine receptors, with different
kinetics for each receptor [67]. Without agreeing on a sin-
gle mode-of-action, various reports have thus already de-
scribed direct and indirect pro-migratory effects of
adenosine on monocyte. Consistent with its overall anti-
inflammatory effect, adenosine may, in contrast, also re-
duce the migration of pro-inflammatory cell types [68].
This may also apply to activated monocytes and microglia
which were reported to migrate less in response to activa-
tion of the A3 adenosine receptor [69]. Adenosine was
further found to slow the migration of dendritic cells [70]
and to inhibit transendothelial migration of conventional
T cells via an indirect monocyte-dependent mechanism
[71]. While these divergent effects may be due to cell type
and activation state-dependent expression patterns of
adenosine receptors A1, A2A, A2B and A3, the analysis of
receptor distribution is hampered by the lack of suitable
antibodies against the individual receptor subtypes. Still, it
appears clear that adenosine can affect cell migration via
direct and indirect mechanisms involving different adeno-
sine receptors depending on cell type, assay and kinetics.
Conclusion
Our findings that human monocytes are attracted by ad-
enosine while M2 macrophages can contribute to local
immunosuppression via adenosine generation suggest a
self-amplifying mechanism: Similar to what has already
been described in mice [40] and what needs to be fur-
ther explored in vivo, tumor-derived adenosine might
promote recruitment of further adenosine-generating
cells towards the microenvironment in human cancer
patients. Infiltration with MDSC or TAM would then be
both a consequence and a further source of tumor-derived
adenosine. This might further explain the very potent
effects observed with anti-CD73 and anti-ADORA2A di-
rected strategies in animal tumor models [8, 10, 55] – and
it could show a new strategy to interfere with MDSC,
TAM and their tumor-promoting role in ovarian cancer.
Importantly, the substances we used to specifically block
CD39 and CD73 activity are already being tested in vivo
for other diseases: APCP was found to be highly beneficial
in a mouse melanoma model [72] whereas the CD39-
inhibitor ARL67156 has shown promise for the treatment
of hepatic insulin resistance [73]. Thus, such inhibitors
might also become available for the clinical treatment of
malignant diseases. Based on previous findings and on the
data outlined in this manuscript, there certainly is a strong
rationale for a potential use of ectonucleotidase inhibitors
in the immunotherapeutic treatment of ovarian cancer.
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